- Home
- ELUT vs FENC Comparison
ELUT vs FENC Comparison
Compare ELUT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELUT
- FENC
- Stock Information
- Founded
- ELUT 2015
- FENC 1996
- Country
- ELUT United States
- FENC United States
- Employees
- ELUT 54
- FENC N/A
- Industry
- ELUT Medical Specialities
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELUT Health Care
- FENC Health Care
- Exchange
- ELUT Nasdaq
- FENC Nasdaq
- Market Cap
- ELUT 145.2M
- FENC 172.8M
- IPO Year
- ELUT 2020
- FENC 2001
- Fundamental
- Price
- ELUT $4.20
- FENC $6.07
- Analyst Decision
- ELUT Strong Buy
- FENC Strong Buy
- Analyst Count
- ELUT 2
- FENC 2
- Target Price
- ELUT $10.00
- FENC $14.00
- AVG Volume (30 Days)
- ELUT 42.1K
- FENC 173.1K
- Earning Date
- ELUT 11-14-2024
- FENC 11-07-2024
- Dividend Yield
- ELUT N/A
- FENC N/A
- EPS Growth
- ELUT N/A
- FENC N/A
- EPS
- ELUT N/A
- FENC N/A
- Revenue
- ELUT $24,782,000.00
- FENC $49,348,000.00
- Revenue This Year
- ELUT $8.00
- FENC $97.94
- Revenue Next Year
- ELUT $39.89
- FENC $11.50
- P/E Ratio
- ELUT N/A
- FENC N/A
- Revenue Growth
- ELUT N/A
- FENC 278.09
- 52 Week Low
- ELUT $1.86
- FENC $3.96
- 52 Week High
- ELUT $5.24
- FENC $11.92
- Technical
- Relative Strength Index (RSI)
- ELUT 52.78
- FENC 61.50
- Support Level
- ELUT $3.90
- FENC $5.77
- Resistance Level
- ELUT $4.40
- FENC $6.35
- Average True Range (ATR)
- ELUT 0.39
- FENC 0.39
- MACD
- ELUT -0.04
- FENC -0.02
- Stochastic Oscillator
- ELUT 24.59
- FENC 51.62
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.